As no definitive therapy or vaccine is yet available for COVID-19, in a desperate attempt repurposed drugs are being explored as an option. A drug repurposing study identified Ciclesonide as a potential candidate. We reviewed the available evidence and clinical trials on the use of Ciclesonide in COVID-19. At present the evidence is limited to a report of three cases. However, five clinical trials are underway, and their results will help in elucidating the role of Ciclesonide in COVID-19.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.5603/ARM.a2020.0173 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!